Key result
Beta-blocker therapy lacks reported quantitative data regarding its impact on exercise capacity in HFpEF.
Why the study?
Beta-blockers are frequently prescribed in HFpEF based on extrapolation from HFrEF, but their benefit is uncertain and they may limit exercise capacity.
Does beta-blocker therapy reduce peak VO2 in patients with heart failure with preserved ejection fraction?
Meta-Analysis
Does beta-blocker therapy reduce peak VO2 in patients with heart failure with preserved ejection fraction?
Answers are grounded in this paper and cite their sources.
Beta-blocker therapy in patients with HFpEF is associated with a significant reduction in objective functional capacity as measured by peak VO2.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Giorgi et al. (2026) conducted a meta-analysis in Heart Failure with Preserved Ejection Fraction (HFpEF). β-Blocker Therapy was evaluated on Peak VO2. The provided supplementary material does not report the quantitative results regarding the impact of β-blocker therapy on exercise capacity in heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: